Glucagon-like Peptide-1 Agonism With Very Low Calorie Diets

NCT05606471 on ClinicalTrials.gov · last registry update 2022-11-04

45 participants. Its estimated completion date, 28 July 2023, has passed with no update to the record. Primary outcome, as filed: Muscle protein synthesis rate. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: UNKNOWN
Phase: P4
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: University of Nottingham
Sponsor type: Other
Enrollment: 45
Started: 2021-09-15
Primary completion: 2023-07-28 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Muscle protein synthesis rate

Conditions studied

Type 2 Diabetes Mellitus in Obese

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.